A chemical genetics approach for the functional assessment of novel cancer genes

Cancer Research
Qianhe ZhouFrank Stegmeier

Abstract

Assessing the functional significance of novel putative oncogenes remains a significant challenge given the limitations of current loss-of-function tools. Here, we describe a method that employs TALEN or CRISPR/Cas9-mediated knock-in of inducible degron tags (Degron-KI) that provides a versatile approach for the functional characterization of novel cancer genes and addresses many of the shortcomings of current tools. The Degron-KI system allows for highly specific, inducible, and allele-targeted inhibition of endogenous protein function, and the ability to titrate protein depletion with this system is able to better mimic pharmacologic inhibition compared with RNAi or genetic knockout approaches. The Degron-KI system was able to faithfully recapitulate the effects of pharmacologic EZH2 and PI3Kα inhibitors in cancer cell lines. The application of this system to the study of a poorly understood putative oncogene, SF3B1, provided the first causal link between SF3B1 hotspot mutations and splicing alterations. Surprisingly, we found that SF3B1-mutant cells are not dependent upon the mutated allele for in vitro growth, but instead depend upon the function of the remaining wild-type alleles. Collectively, these results demonstrate th...Continue Reading

Associated Datasets

References

May 20, 2003·Nature Biotechnology·Aimee L JacksonPeter S Linsley
Feb 21, 2006·Nature Methods·Amanda BirminghamAnastasia Khvorova
May 10, 2006·RNA·Yuriy FedorovAnastasia Khvorova
Feb 20, 2009·Proceedings of the National Academy of Sciences of the United States of America·Surojit SurNickolas Papadopoulos
Sep 21, 2010·Chemistry & Biology·Mari IwamotoThomas J Wandless
Jan 21, 2011·Nature·Raphaël Margueron, Danny Reinberg
Jul 5, 2011·Nature Chemical Biology·Kimberly M BongerThomas J Wandless
Sep 1, 2011·Nature Reviews. Drug Discovery·Asher Mullard
Oct 15, 2011·The New England Journal of Medicine·E PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Dec 14, 2011·The New England Journal of Medicine·Lili WangCatherine J Wu
Dec 23, 2011·Molecular Cancer Therapeutics·Sauveur-Michel MairaCharles F Voliva
Mar 31, 2012·Nature·C Glenn Begley, Lee M Ellis
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Sep 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Giedrius GasiunasVirginijus Siksnys
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Oct 2, 2012·Nature Chemical Biology·Sarah K KnutsonKevin W Kuntz
Dec 14, 2012·Proceedings of the National Academy of Sciences of the United States of America·Wei QiEn Li
Jan 5, 2013·Science·Le CongFeng Zhang
Jan 15, 2013·Nature Genetics·J William HarbourAnne M Bowcock
Jul 19, 2013·Cancer Discovery·Simon J FurneyRichard Marais
Feb 14, 2014·Wiley Interdisciplinary Reviews. RNA·Kenichi Yoshida, Seishi Ogawa
Jun 20, 2014·Future Medicinal Chemistry·Yujeong JeongSungwoo Hong

❮ Previous
Next ❯

Citations

Jun 11, 2016·Nature Reviews. Cancer·Heidi DvingeRobert K Bradley
Sep 8, 2016·Nature Medicine·Stanley Chun-Wei Lee, Omar Abdel-Wahab
Mar 30, 2017·Blood·Poorval JoshiOmar Abdel-Wahab
Jun 1, 2018·Endocrine-related Cancer·Abigail Read, Rachael Natrajan
Aug 9, 2019·The Journal of Clinical Investigation·W Brian DaltonBen Ho Park
Jun 16, 2017·Clinical Chemistry·Eric S ChristensonBen Ho Park
Jul 12, 2019·Science Translational Medicine·Sabrina BonduMichaëla Fontenay
Jul 25, 2019·Genes, Chromosomes & Cancer·Justin Taylor, Stanley C Lee
Sep 10, 2020·Biomarker Research·Zhixia ZhouPeifeng Li
May 31, 2018·Clinical & Experimental Metastasis·Diego M MarzeseDave S B Hoon
Jan 15, 2019·Cancer Cell International·Debarati GhoshSonali Bhattacharjee
Mar 28, 2018·Nature Chemical Biology·Behnam NabetJames E Bradner
Oct 16, 2019·Cancer Discovery·Esther A ObengOmar Abdel-Wahab
Nov 12, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Akihide Yoshimi, Omar Abdel-Wahab
Oct 9, 2020·The Journal of Clinical Investigation·Bo LiuSarat Chandarlapaty
Dec 29, 2020·Advances in Biological Regulation·Andrea Pellagatti, Jacqueline Boultwood
Feb 26, 2019·Cancer Cell·Eric WangIannis Aifantis
Jul 19, 2018·Progress in Lipid Research·Nishikant WaseConcetta DiRusso
Jun 3, 2021·International Journal of Molecular Sciences·Maxime BlijlevensVictor W van Beusechem
Aug 5, 2017·Chemical Reviews·George M Burslem, Craig M Crews
Jun 23, 2021·Blood·Sisi ChenOmar Abdel-Wahab
Sep 22, 2021·The Journal of Clinical Investigation·Brian A WaduguMatthew J Walter

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.